HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft.

Abstract
Intraperitoneal (IP) therapy with platinum (Pt)-based drugs has shown promising results clinically; however, high locoregional concentration of the drug could lead to adverse side effects. In this study, IP administration was coupled with a folate receptor-targeted (FRT) liposomal system, in an attempt to achieve intracellular delivery of the Pt-based drug carboplatin in order to increase therapeutic efficacy and to minimize toxicity. In vitro and in vivo activity of FRT carboplatin liposomes was compared with the activity of free drug and nontargeted (NT) carboplatin liposomes using FR-overexpressing IGROV-1 ovarian cancer cells as the model. Significant reduction in cell viability was observed with FRT liposomes, which, compared with the free drug, provided an approximately twofold increase in carboplatin potency. The increase in drug potency was correlated with significantly higher cellular accumulation of Pt resulting from FRT liposomal delivery. Further evaluation was conducted in mice bearing intraperitoneally inoculated IGROV-1 ovarian tumor xenografts. A superior survival rate (five out of six animals) was achieved in animals treated with FRT carboplatin liposomes, injected intraperitoneally with a dose of 15 mg/kg and following a schedule of twice-weekly administration for 3 weeks. In contrast, no survivors were observed in the free drug or NT carboplatin liposome groups. The presence of cancer cells in lung and liver tissues was observed in the saline, free carboplatin, and NT carboplatin liposome groups. However, there was no sign of cancer cells or drug-related toxicity detected in tissues from the animals treated with FRT carboplatin liposomes. The results of this study have demonstrated for the first time that the approach of coupling IP administration with FRT liposomal delivery could provide significantly improved therapeutic efficacy of carboplatin in the treatment of metastatic ovarian cancer.
AuthorsAnumita Chaudhury, Surajit Das, Ralph M Bunte, Gigi N C Chiu
JournalInternational journal of nanomedicine (Int J Nanomedicine) Vol. 7 Pg. 739-51 ( 2012) ISSN: 1178-2013 [Electronic] New Zealand
PMID22359453 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Folic Acid Transporters
  • Liposomes
  • Carboplatin
Topics
  • Animals
  • Carboplatin (administration & dosage, chemistry, pharmacokinetics)
  • Cell Line, Tumor
  • Female
  • Folic Acid Transporters (metabolism)
  • Histocytochemistry
  • Humans
  • Kaplan-Meier Estimate
  • Liposomes (administration & dosage, chemistry, pharmacokinetics)
  • Liver (metabolism, pathology)
  • Lung (metabolism, pathology)
  • Mice
  • Mice, SCID
  • Molecular Targeted Therapy
  • Ovarian Neoplasms (drug therapy, metabolism)
  • Xenograft Model Antitumor Assays

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: